NS4/5 mutations enhance flavivirus Bamaga virus infectivity and pathogenicity in vitro and in vivo.
Animals
Brain
/ pathology
Cell Line
Chlorocebus aethiops
Culicidae
/ virology
Disease Models, Animal
Endoribonucleases
/ metabolism
Female
Flavivirus
/ genetics
Flavivirus Infections
/ metabolism
HEK293 Cells
Humans
Male
Mice
Mosquito Vectors
/ virology
Mutation
Vero Cells
Viral Nonstructural Proteins
/ genetics
Virulence
/ genetics
Virus Replication
West Nile virus
/ genetics
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
12
11
2019
accepted:
23
02
2020
entrez:
24
3
2020
pubmed:
24
3
2020
medline:
15
5
2020
Statut:
epublish
Résumé
Flaviviruses such as yellow fever, dengue or Zika viruses are responsible for significant human and veterinary diseases worldwide. These viruses contain an RNA genome, prone to mutations, which enhances their potential to emerge as pathogens. Bamaga virus (BgV) is a mosquito-borne flavivirus in the yellow fever virus group that we have previously shown to be host-restricted in vertebrates and horizontally transmissible by Culex mosquitoes. Here, we aimed to characterise BgV host-restriction and to investigate the mechanisms involved. We showed that BgV could not replicate in a wide range of vertebrate cell lines and animal species. We determined that the mechanisms involved in BgV host-restriction were independent of the type-1 interferon response and RNAse L activity. Using a BgV infectious clone and two chimeric viruses generated as hybrids between BgV and West Nile virus, we demonstrated that BgV host-restriction occurred post-cell entry. Notably, BgV host-restriction was shown to be temperature-dependent, as BgV replicated in all vertebrate cell lines at 34°C but only in a subset at 37°C. Serial passaging of BgV in Vero cells resulted in adaptive mutants capable of efficient replication at 37°C. The identified mutations resulted in amino acid substitutions in NS4A-S124F, NS4B-N244K and NS5-G2C, all occurring close to a viral protease cleavage site (NS4A/2K and NS4B/NS5). These mutations were reverse engineered into infectious clones of BgV, which revealed that NS4B-N244K and NS5-G2C were sufficient to restore BgV replication in vertebrate cells at 37°C, while NS4A-S124F further increased replication efficiency. When these mutant viruses were injected into immunocompetent mice, alongside BgV and West Nile virus chimeras, infection and neurovirulence were enhanced as determined by clinical scores, seroconversion, micro-neutralisation, viremia, histopathology and immunohistochemistry, confirming the involvement of these residues in the attenuation of BgV. Our studies identify a new mechanism of host-restriction and attenuation of a mosquito-borne flavivirus.
Identifiants
pubmed: 32203536
doi: 10.1371/journal.pntd.0008166
pii: PNTD-D-19-01917
pmc: PMC7089401
doi:
Substances chimiques
NS4A protein, flavivirus
0
NS4B protein, flavivirus
0
NS5 protein, flavivirus
0
Viral Nonstructural Proteins
0
Endoribonucleases
EC 3.1.-
2-5A-dependent ribonuclease
EC 3.1.26.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008166Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Trop Med Hyg. 1982 May;31(3 Pt 1):548-55
pubmed: 6177259
Rev Med Virol. 2015 Jul;25(4):205-23
pubmed: 25828437
Med Vet Entomol. 2003 Dec;17(4):403-11
pubmed: 14651654
J Gen Virol. 2016 May;97(5):1087-1093
pubmed: 26878841
Vet Ital. 2004 Oct-Dec;40(4):502-7
pubmed: 20422577
J Virol. 2006 Jul;80(14):7009-19
pubmed: 16809306
J Virol. 2011 Nov;85(21):11274-82
pubmed: 21880777
J Virol. 2006 Mar;80(6):2987-99
pubmed: 16501108
J Med Entomol. 2010 May;47(3):466-72
pubmed: 20496595
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8496-501
pubmed: 27402752
PLoS One. 2012;7(6):e39387
pubmed: 22724010
Am J Trop Med Hyg. 2018 Mar;98(3):841-844
pubmed: 29313469
Sci Rep. 2017 Jun 7;7(1):2940
pubmed: 28592864
Biotechniques. 1991 Apr;10(4):484, 486
pubmed: 1651093
J Gen Virol. 1979 Apr;43(1):247-52
pubmed: 113494
J Anim Ecol. 2010 May;79(3):610-9
pubmed: 20180875
J Virol. 1994 Jul;68(7):4580-8
pubmed: 8207832
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006886
pubmed: 30356234
Annu Rev Microbiol. 1990;44:649-88
pubmed: 2174669
J Gen Virol. 2006 Feb;87(Pt 2):329-37
pubmed: 16432019
Emerg Infect Dis. 2005 Feb;11(2):225-31
pubmed: 15752439
PLoS Pathog. 2017 Apr 27;13(4):e1006254
pubmed: 28448634
Antiviral Res. 2016 Jun;130:69-80
pubmed: 26996139
Vector Borne Zoonotic Dis. 2017 Mar;17(3):161-164
pubmed: 28145811
J Virol Methods. 2000 Jun;87(1-2):13-23
pubmed: 10856748
J Virol. 2003 Jul;77(14):7804-13
pubmed: 12829820
J Virol. 2014 Sep 1;88(17):9947-62
pubmed: 24942584
PLoS Pathog. 2017 Dec 27;13(12):e1006788
pubmed: 29281739
Int J Exp Pathol. 2012 Feb;93(1):24-33
pubmed: 22264283
J Gen Virol. 2016 Feb;97(2):366-377
pubmed: 26614392
In Vitro Cell Dev Biol Anim. 1993 Apr;29A(4):296-309
pubmed: 8100566
Virology. 2006 Jun 5;349(2):245-53
pubmed: 16624366
J Comp Pathol. 2008 Feb-Apr;138(2-3):72-85
pubmed: 18295788
Intervirology. 1985;24(4):183-92
pubmed: 3000978
Parasit Vectors. 2012 Dec 14;5:293
pubmed: 23241081
J Immunol. 1952 Apr;68(4):473-94
pubmed: 14946386
Curr Opin Virol. 2014 Dec;9:134-42
pubmed: 25462445
Virology. 2012 Apr 10;425(2):82-94
pubmed: 22305622
Virology. 2019 Feb;528:30-36
pubmed: 30554071
Viruses. 2015 Apr 10;7(4):1927-59
pubmed: 25866904
J Virol. 1968 Oct;2(10):955-61
pubmed: 4302013
J Virol. 2010 Nov;84(21):11407-17
pubmed: 20719943
Am J Trop Med Hyg. 1982 Jul;31(4):830-6
pubmed: 6285749
Virology. 2007 Apr 25;361(1):229-41
pubmed: 17178141
J Virol. 2012 May;86(10):5708-18
pubmed: 22379089
mSphere. 2017 Jul 12;2(4):
pubmed: 28713857